To compare vascular risk factors among patients receiving maintenance electroconvulsive therapy (M-ECT) versus acute ECT, and to examine cognitive outcomes associated with M-ECT.
Methods
A retrospective, single-centre, matched case-control study was conducted using a regional Health Service ECT Register (2015–2023). Adults with DSM-5 mood disorders were included. 25 received ≥6 months of M-ECT and 37 received acute-only ECT. Frequency matching achieved similar age structure and sex distribution. Vascular risk factors (hypertension, dyslipidaemia, diabetes, stroke, myocardial infarction, smoking) and a composite “high vascular risk” score (≥2 factors) were compared using Fisher’s exact tests and logistic regression. Cognition was assessed with the Montreal Cognitive Assessment (MoCA) at baseline and longitudinally with linear mixed-effects models.
Results
High vascular risk was common in both groups (M-ECT 76%; acute-only 68%) without significant between-group difference, although dyslipidaemia was more prevalent in the M-ECT group (OR 5.52, 95% CI: 1.51–20.20; p = 0.049). Baseline MoCA was comparable (21.9 vs 22.1) and remained stable during M-ECT (mean change +0.92; 95% CI: −0.51 to +2.35). High vascular risk, not ECT group, predicted cognition (−4.64, 95% CI: −7.45 to −2.01; p = 0.002).
Conclusions
Cognitive performance remained stable during M-ECT. Lower scores were associated with vascular comorbidity, and the higher dyslipidaemia rate underscores the need for cardiometabolic and cognitive monitoring.
SackeimHAHaskettRFMulsantBH, et al.Continuation pharmacotherapy in the prevention of relapse following electroconvulsive therapy: a randomized controlled trial. J Am Med Assoc2001; 285(10): 1299–1307. https://doi.org/10.1001/jama.285.10.1299
2.
RowlandTMannRAzeemS. The efficacy and tolerability of continuation and maintenance electroconvulsive therapy for depression: a systematic review of randomized and observational studies. J ECT2023; 39(3): 141–150. https://doi.org/10.1097/YCT.0000000000000914
3.
GillSPKellnerCH. Clinical practice recommendations for continuation and maintenance electroconvulsive therapy for depression: outcomes from a review of the evidence and a consensus workshop held in Australia in May 2017. J ECT2019; 35(1): 14–20. https://doi.org/10.1097/YCT.0000000000000484
4.
StegmannBGaleCGlueP. Maintenance ECT treatment in New Zealand: local and national data. Australas Psychiatry2023; 31(1): 90–94. https://doi.org/10.1177/10398562221126589
5.
MartinEPurushothamanSBallardE, et al.Electroconvulsive therapy in a tertiary Australian mental health facility between 2009 and 2020. Aust N Z J Psychiatr2024; 58(8): 713–720. https://doi.org/10.1177/00048674241256839
6.
TaylorWDAizensteinHJAlexopoulosGS. The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatr2013; 18(9): 963–974. https://doi.org/10.1038/mp.2013.20
7.
O'ConnorSJHewittNKucJ, et al.Predictors and risk factors of treatment-resistant depression: a systematic review. J Clin Psychiatr2023; 85(1): 23r14885.
8.
TillerJWLyndonRW. Electroconvulsive therapy: an Australasian guide. Australian Postgraduate Medicine. 2003, 2003.
9.
MoirandRGalvaoFLecompteM, et al.Usefulness of the Montreal cognitive assessment (MoCA) to monitor cognitive impairments in depressed patients receiving electroconvulsive therapy. Psychiatry Res2018; 259: 476–481. https://doi.org/10.1016/j.psychres.2017.11.022
10.
MastBTMilesTPenninxBW, et al.Vascular disease and future risk of depressive symptomatology in older adults: findings from the health, aging, and body composition study. Biol Psychiatry2008; 64(4): 320–326. https://doi.org/10.1016/j.biopsych.2008.01.025
11.
KellnerCHHusainMMKnappRG, et al.Right unilateral ultrabrief pulse ECT in geriatric depression: phase 1 of the PRIDE study. Am J Psychiatr2016; 173(11): 1101–1109. https://doi.org/10.1176/appi.ajp.2016.15081101
12.
LisanbySHMcClintockSMMcCallWV, et al.Prolonging remission in depressed elderly (PRIDE) work group. Longitudinal neurocognitive effects of combined electroconvulsive therapy (ECT) and pharmacotherapy in major depressive disorder in older adults: phase 2 of the PRIDE study. Am J Geriatr Psychiatr2022; 30(1): 15–28. https://doi.org/10.1016/j.jagp.2021.04.006
13.
Yoldi-NegreteMGillLNOlivaresS, et al.The effect of continuation and maintenance electroconvulsive therapy on cognition: a systematic review of the literature and meta-analysis. J Affect Disord2022; 316: 148–160. https://doi.org/10.1016/j.jad.2022.08.005
14.
BöslSScheerbaumPGraesselE, et al.My patient might be depressed - can I still screen for MCI? Exploring cognitive performance on the MoCA in older people screened for depressive symptoms with the PHQ-9. BioMedCentral Geriatrics2025; 25(1): 374. https://doi.org/10.1186/s12877-025-06004-6
15.
ClassonEVan den HurkWLythJ, et al.Montreal cognitive assessment: normative data for cognitively healthy Swedish 80- to 94-Year-Olds. J Alzheimers Dis2022; 87(3): 1335–1344. https://doi.org/10.3233/JAD-215629
16.
RatcliffeLNHaleACMcDonaldT, et al.The Montreal cognitive assessment: norms and reliable change indices for standard and MoCA-22 administrations. Arch Clin Neuropsychol2024; 39(6): 747–765. https://doi.org/10.1093/arclin/acae013
17.
ValkanovaVEbmeierKP. Vascular risk factors and depression in later life: a systematic review and meta-analysis. Biol Psychiatry2013; 73(5): 406–413. https://doi.org/10.1016/j.biopsych.2012.10.028
18.
JurekLDoreyJMNourredineM, et al.Impact of vascular risk factors on clinical outcome in elderly patients with depression receiving electroconvulsive therapy. J Affect Disord2021; 279: 308–315. https://doi.org/10.1016/j.jad.2020.10.025
19.
SpaansHPKokRMBouckaertF, et al.Vascular risk factors in older patients with depression: outcome of electroconvulsive therapy versus medication. Int J Geriatr Psychiatr2018; 33(2): 371–378. https://doi.org/10.1002/gps.4754
20.
Fernández-CandilJCastelltortMLFàbregasJN, et al.Anaesthesia in electroconvulsive therapy. Special conditions. Revista de Psiquiatria Salud Mental English Edition2020; 13(1): 36–46.
EliasADasSKirklandJ, et al.Safety of electroconvulsive therapy in the context of physiological and medical complexity: a state-of-the art review. Psychiatry and Clinical Neurosciences Reports2025; 4(1): e70051. https://doi.org/10.1002/pcn5.70051
23.
GoracciARucciPForgioneRN, et al.Development, acceptability and efficacy of a standardized healthy lifestyle intervention in recurrent depression. J Affect Disord2016; 196: 20–31. https://doi.org/10.1016/j.jad.2016.02.034
24.
MarxWMangerSHBlencoweM, et al.Clinical guidelines for the use of lifestyle-based mental health care in major depressive disorder: World Federation of societies for biological psychiatry (WFSBP) and Australasian society of lifestyle medicine (ASLM) taskforce. World J Biol Psychiatr2023; 24(5): 333–386. https://doi.org/10.1080/15622975.2022.2112074
25.
LuccarelliJMcCoyTHJrSeinerSJ, et al.Maintenance ECT is associated with sustained improvement in depression symptoms without adverse cognitive effects in a retrospective cohort of 100 patients each receiving 50 or more ECT treatments. J Affect Disord2020; 271: 109–114. https://doi.org/10.1016/j.jad.2020.03.152
26.
BernardoffLBlayMThellierD, et al.Impact of anesthesia on electroconvulsive therapy-related impairments in global cognitive function in patients with treatment-resistant depression. J ECT2026; 42(1): 19–23. https://doi.org/10.1097/YCT.0000000000001119
